#nsclc

Biomarkers in NSCLC
Biomarkers in NSCLC
The Future of Local Therapy in Lung Cancer
The Future of Local Therapy in Lung Cancer
Local Therapy for Patients with Oligoprogressive NSCLC
Local Therapy for Patients with Oligoprogressive NSCLC
Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation
Targeted Therapy Before Surgery in Patients with Resectable NSCLC and Driver Mutation
Local Therapy for NSCLC Patients After Frontline Therapy
Local Therapy for NSCLC Patients After Frontline Therapy
Treatment Options for Patients with Locally Advanced Unresectable NSCLC
Treatment Options for Patients with Locally Advanced Unresectable NSCLC
Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
Immunotherapy for Patients with Resectable NSCLC and a Driver Mutation
Local Therapy for Limited Metastatic NSCLC
Local Therapy for Limited Metastatic NSCLC
Neoadjuvant Treatment for Patients with NSCLC
Neoadjuvant Treatment for Patients with NSCLC
The Alina Trial for ALK+ NSCLC
The Alina Trial for ALK+ NSCLC
20 - Selpercatinib come trattamento di II linea nel trattamento del NSCLC con mutazioni di RET
20 - Selpercatinib come trattamento di II linea nel trattamento del NSCLC con mutazioni di RET
19 - Rimborsabilità di cemiplimab nel NSCLC non-oncogene addicted localmente avanzato non resecabile o metastatico con PD-L1>50%
19 - Rimborsabilità di cemiplimab nel NSCLC non-oncogene addicted localmente avanzato non resecabile o metastatico con PD-L1>50%
16 - Atezolizumab nel setting adiuvante del carcinoma polmonare non a piccole cellule
16 - Atezolizumab nel setting adiuvante del carcinoma polmonare non a piccole cellule
ALK+ NSCLC: Tratamiento y Progresión
ALK+ NSCLC: Tratamiento y Progresión
La Importancia de la Terapia Dirigida en NSCLC
La Importancia de la Terapia Dirigida en NSCLC
La Prevalencia de las Pruebas de EGFR en NSCLC en Etapa Temprana
La Prevalencia de las Pruebas de EGFR en NSCLC en Etapa Temprana
Progresión de la Enfermedad en Pacientes con NSCLC EGFR+
Progresión de la Enfermedad en Pacientes con NSCLC EGFR+
Preferential Timing for Molecular Testing in NSCLC
Preferential Timing for Molecular Testing in NSCLC
Circulating Tumor DNA in NSCLC
Circulating Tumor DNA in NSCLC
Testing Methodology for NSCLC: Next Generation Sequencing (NGS)
Testing Methodology for NSCLC: Next Generation Sequencing (NGS)
Testing Methodology for NSCLC: PCR Testing
Testing Methodology for NSCLC: PCR Testing
Testing Methodology for NSCLC: FISH
Testing Methodology for NSCLC: FISH
Testing Methodology for NSCLC: Immunohistochemistry
Testing Methodology for NSCLC: Immunohistochemistry
Gene Mutations in NSCLC
Gene Mutations in NSCLC
Immunotherapy for Oligometastatic Disease
Immunotherapy for Oligometastatic Disease
Immunotherapy for Patients with Driver Mutation
Immunotherapy for Patients with Driver Mutation
Immunotherapy Before Surgery in NSCLC
Immunotherapy Before Surgery in NSCLC
Osimertinib and the FLAURA Trial
Osimertinib and the FLAURA Trial
Choosing First Line Therapy in EGFR Mutations
Choosing First Line Therapy in EGFR Mutations
Advancements of Targeted Therapy for EGFR Mutations in NSCLC
Advancements of Targeted Therapy for EGFR Mutations in NSCLC
Prevalence of EGFR-Mutant NSCLC in Asian and Caucasian Communities
Prevalence of EGFR-Mutant NSCLC in Asian and Caucasian Communities
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Lecia Sequist: Can We Bring The Advances in Targeted Therapy to Squamous NSCLC and Broader NSCLC Populations?
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sarah Goldberg: The Potential Value of a Treatment Break as an Alternative to Maintenance Therapy in Advanced NSCLC
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
Dr. Sandler on Options for Maintenance Therapy: Switch, Continuation, or a Treatment Break?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?
Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Dr. Heather Wakelee: My Approach to Repeat Biopsies For Advanced NSCLC Patients Who Have Insufficient Tissue for Molecular Testing
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Do You Seek and Do You Use Molecular Marker Information in Patients with Early Stage NSCLC?
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Dr. Geoffrey Oxnard on Translating the Benefits of Molecular Oncology More Broadly: The Tissue is the Issue
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
Highlights in Lung Cancer, 2012: New Options for EGFR Mutation-Positive NSCLC (audio)
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Dr. Lecia Sequist on Relevant Emerging Molecular Targets in Lung Cancer
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)
Highlights in Lung Cancer, 2012: ALK Inhibitors for Patients with ALK or ROS1 Gene Rearrangements (audio)
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
Highlights in Lung Cancer, 2013, Part 4: Squamous Cell NSCLC and antiPD1 Immunotherapy (video)
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (audio)
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Drs. Ross Camidge and Corey Langer: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Greg Riely on "I just found out I have an EGFR mutation, and I'm in the middle of chemo. What now?"
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Lecia Sequist: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)
Highlights in Lung Cancer, 2013, Part 5: Maintenance Therapy in Advanced NSCLC (video)
Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?
Dr. Phil Bonomi: Is Maintenance Therapy after First Line Chemotherapy a Mandate, An Option, or a Neither?
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Dr. Sarah Goldberg: What Methods Do I Use to Obtain Samples for Molecular Testing?
Sto caricando